Detection of V617F point mutation of JAK2 gene by real-time PCR in chronic myeloproliferative disease
10.3760/cma.j.issn.1009-9921.2010.09.009
- VernacularTitle:实时定量聚合酶链反应检测慢性骨髓增殖性疾病患者JAK2 V617F基因突变
- Author:
Jian ZHOU
;
Yanli ZHANG
;
Xiaodong Lü
;
Xudong WEI
;
Ruihua FAN
;
Baijun FANG
;
Yongping SONG
- Publication Type:Journal Article
- Keywords:
Myeloproliferative disorders;
Gene,JAK2;
Genes;
Mutation;
Polymerase chain relation
- From:
Journal of Leukemia & Lymphoma
2010;19(9):542-544
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the novel V617F point mutation of JAK2 gene by real-time PGR in the patients with chronic myeloproliferative disease (CMPD) and evaluate its clinical significance. Methods Genomic DNA from bone marrow or peripheral blood mononuclear cells was extracted from 56 patients with CMPD, including 26 cases of polycythemia vera (PV), 24 cases of essential thrombocythemia (ET), 5 cases of chronic idiopathicmyelofibrosis (CIMF) and 1 case of high eosinophilic syndrome (HES). The exon 14 of JAK2 gene which harbourd V617F mutation were screened by real-time PGR. Results JAK2 V617F mutation was measured in 29 of the 56 patients with CMPD. The prevalence of mutation was 65.38 %(17/26) in PV,37.50 % in ET and 60.00 %(3/5) in CIMF. The proportion of mutation in PV, ET and CIMF are respectively 53.85 %(14/26), 29.17 %(7/24), 40.0 %(2/5) in heterozygotes and 11.54 %(3/26), 8.33 %(2/24), 20.00 %(1/5)in homozygotes. JAK2 mutation was negative in one patient with HES. JAK2 V617F allele burden in PV, ET and CIMF are respectively 2.14×102-1.5×107, 9.80×102-4.4×107 and 4.10×103-3.70×106 copies. Conclusion Real-time PCR is a useful tool for pre cisely assess the grade of mutant allele burden as well as to screen JAK2V617F mutation simultaneously, which is simple and convenient to carry out in clinical laboratories for diagnosis and further evaluations of minimal residual disease in CMPD patients.
